Exhibit 10.5


 


PATENT & TECHNOLOGY
LICENSE AGREEMENT


 


This Patent and Technology License Agreement
(“Agreement”) is effective on March 15, 2018 (the “Effective Date”) and is entered by and
between Loma Linda University (“LLU”), a California Religious Institution, whose address is 24887 Taylor Street,
Suite 201, Loma Linda, California 92354, and ADiTx Therapeutics, Inc., a Delaware C Corporation, with its principal place of business
at 11161 Anderson St., Suite 105-10014, Loma Linda, CA 92354 (“Licensee”) (collectively, “Parties”,
or singly, “Party”).


 


No binding agreement between the Parties
will exist until this Agreement has been signed by both Parties. Unsigned drafts of the Agreement shall not be considered offers.


 


Background


 


LLU owns Licensed Subject Matter (defined
below). LLU has determined that development and commercialization of the Licensed Subject Matter is in the public’s best
interest and is consistent with LLU’s educational and research missions and goals. LLU desires to have the Licensed Subject
Matter developed and commercialized for the benefit of Licensee, the Inventors, LLU and the public.


 


WHEREAS, the Licensed Subject Matter was
licensed to Sekris Biomedical Corporation (“Sekris”) under the Patent & Technology License Agreement (the “Prior
Agreement”) between Sekris and LLU effective May 25, 2011, the First Amendment to the Prior Agreement effective June 24,
2011, the Second Amendment to the Prior Agreement effective July 16, 2012, the Third Amendment to the Prior Agreement effective
December 27, 2012 (collectively “Amendments to the Prior Agreement”);


 


WHEREAS, Sekris assigned to Licensee on
March 8, 2018 all rights and interests pursuant to Section 12.2 of the Prior Agreement and Amendments to the Prior Agreement;
and


 


WHEREAS, Licensee desires to amend and
restate the license from LLU to practice the Licensed Subject Matter, which license will supersede any prior agreement entered
between LLU and Licensee, and the Prior Agreement and Amendments to the Prior Agreement between LLU and Sekris, as provided herein.


 


NOW, THEREFORE, for and in consideration
of mutual covenants and agreements contained herein, and the other good and valuable consideration, the receipt and legal sufficiency
of which are hereby acknowledged, the Parties hereby agree as follows:


 


		1.	Definitions: When capitalized,
                                         the following terms will have the following meanings:



 


“Affiliate”
means any business entity more than fifty percent (50%) owned by Licensee, any business entity which owns more than fifty percent
(50%) of Licensee, or any business entity that is more than 50% owned by a business entity that owns more than fifty percent (50%)
of Licensee.


 


“Contract Quarter”
means the three-month periods ending on March 31, June 30, September 30 and December 31, or any stub period thereof at the commencement
of this Agreement or the expiration or termination of this Agreement.


 


“Contract Year” means the 12-month
period ending on December 31, or any stub period thereof at the commencement of this Agreement or the expiration or termination
of this Agreement.


 


“FDA” means United States Food
and Drug Administration.


 


“Field” means research and clinical
use for all uses.


 







    1


     


    

 


“Government”
means any branch, department, agency, or other unit of the United States of America or the State of California.


 


“Gross Consideration” means all
cash and non-cash consideration (e.g., securities).


 


“Inventors” (or singly, “Inventor”)
means the individuals listed on Exhibit A.


 


“Licensed Process”
means a method or process whose practice or use is covered by a Valid Claim and/or incorporates or uses Patent Rights or Technology
Rights.


 


“Licensed Product”
means any product or component (a) the manufacture, use, sale, offer for sale or import of which is covered by a Valid Claim,
and/or incorporates or uses any Patent Rights or Technology Rights, or (b) which is made using a Licensed Process.


 


“Licensed Service”
means performance of a service using a Licensed Product, or the practice of a Licensed Process. For clarity, non-profit research
and development of Licensed Products by Licensee, its Affiliates, or Sublicensees do not constitute a Licensed Service.


 


“Licensed Subject Matter” means
Patent Rights and/or Technology Rights.


 


“Milestone Fees” means all fees
identified as Milestone Fees in Section 3.1(c).


 


“Net Product Sales”
means the Gross Consideration from the Sale of Licensed Products less the following items directly attributable to the Sale of
such Licensed Products that are specifically identified on the invoice for such Sale and borne by the Licensee, Affiliates, or
Sublicensees as the seller: (a) discounts and rebates actually granted; (b) sales, value added, use and other taxes and government
charges actually paid, excluding income taxes; (c) import and export duties actually paid; (d) freight, transport, packing and
transit insurance charges actually paid or allowed; and (e) other amounts actually refunded, allowed or credited due to rejections
or returns, but not exceeding the original invoiced amount. Net Product Sales exclude a reasonable quantity used internally by
Licensor, its Affiliates or Sublicensees solely for testing or quality control purposes, marketing or demonstration purposes,
or seeking governmental approval (e.g., FDA clinical trials).


 


“Net Service Sales”
means the Gross Consideration received from the Sale of Licensed Services less the following items, directly attributable to the
Sale of such Licensed Services that are specifically identified on the invoice for such Sale and borne by the Licensee, Affiliates,
or Sublicensees as the seller: (a) discounts and rebates actually granted; (b) sales, value added, use and other taxes and government
charges actually paid, excluding income taxes; and (c) other amounts actually refunded, allowed or credited due to rejections
or re-works, but not exceeding the original invoiced amount.


 


“Non-Royalty Sublicensing
Consideration” means the Gross Consideration received by the Licensee or its Affiliate from a Sublicensee in consideration
of the grant of a sublicense under the Licensed Subject Matter (including, without limitation, license or option or distribution
fees, fees to maintain license rights, and bonus/milestone payments), but excluding amounts received as running royalties or other
revenue sharing based on Net Product Sales or Net Service Sales for which LLU receives a running royalty under Section 3.2.
For the avoidance of doubt, Non-Royalty Sublicensing Consideration shall not include bona fide: (a) running royalties received
by Licensee or an Affiliate based on Net Product Sales or Net Service Sales that are royalty-bearing to LLU under Section 3.2,
(b) purchase price for Licensee’s stock or other securities not in excess of fair market value, and (c) amounts paid and
used exclusively for research and development of Licensed Products or Licensed Services by Licensee.


 




    2


     


    

 


“Patent Rights”
means the LLU’s rights in: (a) the patents and patent applications listed in Exhibit A to this Agreement; (b) all
non-provisional patent applications that claim priority to any of the provisional applications listed in Exhibit A provided
that the claims of such non-provisional applications are entitled to claim priority to such provisional applications; (c) all
divisionals, continuations and continuations-in-part of the non-provisional patent applications identified in (a) and (b), above
provided that the claims of such continuations-in-part are entitled to claim priority to at least one of the patent applications
identified in (a) or (b), above; (d) all reissues, reexaminations, extensions, and foreign counterparts of any of
the patents or patent applications identified in (a), (b) or (c), above; and (e) any patents that issue with
respect to any of the patent applications listed in (a), (b), (c) or (d), above.


 


“Prosecution Counsel”
means the law firm or attorney who is handling the prosecution of the Patent Rights. U.S. Prosecution Counsel as of the Effective
Date is identified in Exhibit A to this Agreement.


 


“Quarterly Payment
Deadline” means the day that is thirty (30) days after the last day of any particular Contract Quarter.


 


“Regulatory Approval”
means the approval by the Regulatory Authority needed for a particular national jurisdiction to market, Sell and use a Licensed
Product or Licensed Service in that national jurisdiction.


 


“Regulatory Authority”
means the governmental authority responsible for granting any necessary licenses or approvals for the marketing, Sale and use
of a Licensed Product or Licensed Service in a particular national jurisdiction, including without limitation, the FDA, European
Medicines Agency or Koseisho (i.e. the Japanese Ministry of Health and Welfare).


 


“Sell, Sale or Sold” means any transfer or other disposition of Licensed Products or Licensed Services for which consideration is received
by Licensee, its Affiliates or Sublicensees. A Sale of Licensed Products or Licensed Services will be deemed completed at the
time Licensee or its Affiliate or its Sublicensee receives such consideration.


 


“Sublicense Agreement”
means any agreement or arrangement pursuant to which Licensee (or an Affiliate or Sublicensee) grants to any third party any of
the license rights granted to the Licensee under this Agreement.


 


“Sublicense Fees” means the fees
specified in Section 3.1(d).


 


“Sublicensee”
means any entity to whom an express sublicense has been granted under the Patent Rights and/or Technology Rights. For clarity,
a third party wholesaler or distributor who has no significant responsibility for marketing and promotion of the Licensed Product
or Licensed Services within its distribution territory or field (i.e., the third party simply functions as a reseller), and who
does not pay any consideration to Licensee or an Affiliate for such wholesale or distributor rights, shall not be deemed a Sublicensee
and the resale by such a wholesaler or distributor shall not be treated as royalty bearing Net Sales by a Sublicensee, provided
that a royalty is being paid by Licensee for the initial transfer to the wholesaler or distributor pursuant to Section 3.2.
This definition does not limit Licensee’s rights to grant or authorize sublicenses under this Agreement.


 


“Technology Rights”
means LLU’s rights in technical information, know-how, processes, procedures, compositions, devices, methods, formulas,
protocols, techniques, designs, drawings or data created before the Effective Date by Inventors while employed at LLU and within
the Field which are not covered by a Valid Claim but which are necessary for practicing inventions claimed in patents and/or patent
applications listed in the definition of Patent Rights.


 




    3


     


    

 


“Territory” means worldwide.


 


“Valid Claim”
means a claim of (a) an issued and unexpired patent included within the Patent Rights unless the claim has been held unenforceable
or invalid by the final, un-reversed, and un-appealable decision of a court or other governmental body of competent jurisdiction,
has been irretrievably abandoned or disclaimed, or has otherwise been finally admitted or finally determined by the relevant governmental
authority to be invalid, un-patentable or unenforceable, whether through reissue, reexamination, disclaimer or otherwise, or (b)
a pending patent application within the Patent Rights to the extent the claim continues to be prosecuted in good faith.


 


		2.	License Grant and Commercialization



 


		2.1	Grant



 


		(a)	LLU grants to Licensee
                                         a royalty-bearing exclusive license under Patent Rights to manufacture, have manufactured,
                                         use, offer for Sale, Sell and/or import Licensed Products in the Field in the Territory
                                         and to perform Licensed Services in the Field in the Territory.



 


		(b)	LLU grants to Licensee a royalty-bearing
                                         exclusive license under Technology Rights to manufacture, have manufactured, use, offer
                                         for Sale, Sell and/or import Licensed Products in the Field in the Territory and to perform
                                         Licensed Services in the Field in the Territory.



 


		(c)	This grant is subject to (i) the
                                         payment by Licensee to LLU of all consideration required under this Agreement, (ii) any
                                         rights of, or obligations to, the Government as set forth in Section 11.2 (Government
                                         Rights), and (iii) rights retained by LLU to:



 


		(1)	Publish the scientific findings from research
                                         related to the Patent Rights; and



 


		(2)	Use the Licensed Subject Matter for teaching, research, education,
                                         and other educationally-related purposes; and



 


		(3)	Grant rights to, and transfer material
                                         embodiments of, the Licensed Subject Matter to other academic institutions or non-profit
                                         research institutions for the purposes identified in Sections 2.1(c)(1) and 2.1(c)(2)(b),
                                         above.



 


		(d)	LLU reserves all rights not expressly granted in this Agreement
                                         and disclaims the grant of any implied rights to Licensee.



 


		2.2	Affiliates



 


Licensee may extend the license
granted herein to any Affiliate provided that the Affiliate agrees in writing to be bound by this Agreement to the same extent
as Licensee. For the sake of clarity, any specific reference to “Licensee” in any provision of this Agreement
shall include such Affiliate regardless of whether a specific reference to an “Affiliate” is made in such provision.
Licensee shall deliver such Affiliate’s written agreement to LLU within thirty (30) calendar days following execution.


 




    4


     


    

 


		2.3	Sublicensing



 


Licensee has the right to grant
Sublicense Agreements under the Licensed Subject Matter consistent with the terms of this Agreement, subject to the following:


 


		(a)	A Sublicense Agreement
                                         shall not exceed the scope and rights granted to Licensee hereunder. Sublicensee must
                                         agree in writing to be bound by the applicable terms and conditions of this Agreement
                                         and shall agree that LLU is a third party beneficiary of the Sublicense Agreement. In
                                         the event of termination of this Agreement, continued sublicense rights shall be governed
                                         by Section 7.5(a). Licensee may grant a Sublicensee the right to grant further
                                         sub-Sublicense Agreements consistent with this Agreement, in which case such sub-Sublicense
                                         Agreements shall be treated as “Sublicense Agreements” and such sub-Sublicensees
                                         shall be treated as “Sublicensees” for purposes of this Agreement.



 


		(b)	Licensee shall deliver to LLU a true,
                                         complete, and correct copy of each Sublicense Agreement granted by Licensee, Affiliate
                                         or Sublicensee, and any modification or termination thereof, within thirty (30) days
                                         following the applicable execution, modification, or termination of such Sublicense Agreement.
                                         If the Sublicense Agreement is not in English, Licensee shall provide LLU an accurate
                                         English translation in addition to a copy of the original agreement.



 


		(c)	Notwithstanding
                                         any such Sublicense Agreement, Licensee will remain primarily liable to LLU for all of
                                         the Licensee’s duties and obligations contained in this Agreement, including without
                                         limitation the payment of running royalties due under Section 3.2 whether or not
                                         paid to Licensee by a Sublicensee. Any act or omission of a Sublicensee that would be
                                         a breach of this Agreement if performed by Licensee will be deemed to be a breach by
                                         Licensee, provided that, if Licensee cures Sublicensee’s breach within ninety (90) days
                                         of Sublicensee’s breach, then the Sublicensee’s breach will be considered cured and no
                                         longer considered a breach. Each Sublicense Agreement will contain a right of termination
                                         by Licensee in the event that the Sublicensee breaches the payment or reporting obligations
                                         affecting LLU or any other terms and conditions of the Sublicense Agreement that would
                                         constitute a breach of this Agreement if such acts were performed by Licensee.



 


		2.4	Diligent
                                         Commercialization



 


Licensee by itself or through
its Affiliates and Sublicensees will use diligent efforts to make Licensed Products and/or Licensed Services (as applicable) commercially
available in the Field within the Territory. Without limiting the foregoing, Licensee will:


 


		(a)	maintain a bona
                                         fide, funded, ongoing and active research, development, manufacturing, regulatory, marketing
                                         or sales program (all as commercially reasonable) to make License Products and/or Licensed
                                         Services commercially available in the Field to the public as soon as commercially practicable
                                         within the Territory, and



 




    5


     


    

 


		(b)	achieve the following Diligence Milestone events by the deadlines
                                         indicated:



 


	Diligence
    Milestone Events	 	Deadlines
	 	 	 
	Completion of financing round	 	July 31, 2018 
	 	 	 
	Regulatory approval of IND application to initiate first-in-human clinical trials	 	March 31, 2020
		 	 
	Completion of
    first-in-human (phase I/II) clinical trials	 	March 31, 2022
		 	 
	Completion of
    Phase III clinical trials	 	March 31, 2024
	 	 	 
	Biologic Licensing
    Approval by FDA	 	March 31, 2025


 


		(c)	If the obligations under Sections 2.4 (a) and 2.4(b)
                                         are not fulfilled, LLU may treat such failure as a breach in accordance with Section
                                         7.3(b).



 


		(d)	Licensee may extend any of the deadlines for
                                         achieving the Diligence Milestones set forth in Section 2.4(b) above, up to a maximum
                                         of three (3) times, upon written notice to LLU requesting an extension and full payment
                                         of the Extension Fee, as defined below prior to expiration of the deadline. For purposes
                                         of this Agreement, the term “Extension Fee” shall mean one hundred thousand
                                         dollars ($100,000) for each extension request. Upon payment of each Extension Fee with
                                         respect to any of the Diligence Milestones, an additional year will be added to the time
                                         for completion of such Diligence Milestone and all other as yet unmet Diligence Milestones.
                                         It is understood and agreed that time is of the essence with respect to payment of the
                                         Extension Fee, and failure to timely pay an Extension Fee shall not be subject to any
                                         cure period.



 


		3.	Compensation



 


In consideration of rights granted
to Licensee, Licensee will pay LLU the following fees and royalties. All fees and royalties are not refundable and are not creditable
against other fees and royalties. Payments shall be made as specified in Section 18.2.


 


		3.1	Non-Royalty Payments due from Licensee



 


		(a)	Patent Expenses. Licensee will pay all Patent Expenses
                                         in accordance with Article 6.



 


		(b)	Scheduled License Fees. Licensee will pay license fees
                                         in the following amounts and in accordance with the following schedule.



 


		(i)	Upfront License
                                         Fee: Licensee shall pay an Upfront License Fee of twenty five thousand dollars ($25,000)
                                         due (without invoice) within thirty (30) days of either the Effective Date or the date
                                         this Agreement has been fully executed by all Parties, whichever is later (“Upfront
                                         License Fee”). Licensee’s obligations to pay all future patent expenses
                                         pursuant to Article 6 (Patent Expenses and Prosecution) will not be limited by
                                         such amount. The Upfront License Fee shall not be subject to the thirty (30) day cure
                                         period set forth in Section 7.3(a), below.



 


		(ii)	Annual Fees: Licensee shall pay the following Annual Fees:



 


Twenty five thousand dollars ($25,000) due on March
31, 2020, and every anniversary thereafter until the termination of this agreement.


 






    6


     


    

 


		(c)	Milestone Fees. Licensee will pay Milestone Fees within thirty
                                         (30) days of achieving the following milestone events:



 


	Milestone
    Events	 	Milestone
    Fees
	Completion of financing round (estimated in
    Section 2.4(b) to be on or before July 31, 2018)	 	Two hundred thousand dollars ($200,000)
	 	 	 
	Regulatory  approval  of  IND  application  to
    initiate first-in-human clinical trials (estimated in Section 2.4(b) to be on or before March 31, 2020)	 	One hundred seventy five thousand dollars ($175,000)
	 	 	 
	Completion  of  first-in-human  (phase  I/II)
    clinical trials (estimated in Section 2.4(b) to be on or before March 31, 2022)	 	One hundred thousand dollars ($100,000)
	 	 	 
	Completion  of  Phase  III  clinical  trials
    (estimated in Section 2.4(b) to be on or before March 31, 2024)	 	Five hundred thousand dollars ($500,000)
	 	 	 
	Biologic Licensing Approval by FDA (estimated
    in Section 2.4(b) to be on or before March 31, 2025)	 	Five hundred thousand dollars ($500,000)
	 	 	 
	One time success fee when the combined total
    of Net Product Sales and Net Service Sales are at least fifteen million dollars ($15,000,000) within any single Contract Year	 	Two hundred fifty thousand dollars ($250,000)


 


Licensee shall promptly notify LLU that the milestone
has been achieved as provided in Section 4.1(f).


 


		(d)	Sublicense Fees. Licensee will pay Sublicense
                                         Fees in an amount equal to twenty five percent (25%) of Non-Royalty Sublicensing Consideration
                                         on or before the Quarterly Payment Deadline for the Contract Quarter during which Licensee
                                         receives such consideration.



 


		(e)	Past Patent Fees. Licensee
                                         shall pay LLU two hundred thousand dollars ($200,000) in partial compensation for expenses
                                         incurred by LLU for filing, prosecuting, defending and maintaining Patent Rights. This
                                         payment shall be due on a quarterly basis in three (3) installments, beginning at the
                                         end of the September 2018 and continuing through to the end of March 2019. made in the
                                         amounts of seventy thousand dollars ($70,000) due at the end of September 2018, seventy
                                         thousand dollars ($70,000) due at the end of December 2018, and a final payment of sixty
                                         thousand dollars ($60,000) due at the end of March 2019.



 


		3.2	Royalties



 


Licensee will pay running royalties
on Net Product Sales and Net Service Sales during each Contract Quarter on or before the Quarterly Payment Deadline for such Contract
Quarter, as follows: (a) one and one-half percent (1.5%) of Net Product Sales and Net Service Sales in each Contract Quarter for
Licensed Products and Licensed Services covered by one or more Valid Claims; and (b) three quarter percent (0.75%) of Net Product
Sales and Net Service Sales in each Contract Quarter for Licensed Products and Licensed Services not covered by a Valid Claim
for Technology Rights and know-how for three (3) years beyond the expiration of all applicable Valid Claims. No royalty shall
be payable under this Section 3.2 with respect to (i) Sales to an Affiliate or Sublicensee of a particular unit of Licensed
Product that is used by such Affiliate or Sublicensee to perform a Licensed Service if LLU is paid a royalty on the Sale of such
Licensed Service, (ii) the Sale of Licensed Products between or among Licensee, its Affiliates, and Sublicensees for re-sale purposes,
provided LLU is paid a royalty with respect to the re-sale, or (iii) payments that constitute Non-Royalty Sublicensing Consideration.


 




    7


     


    

 


		3.3	Non-cash
                                         Consideration



 


If Licensee receives or anticipates
receipt of non-cash consideration from Sales or Sublicenses, the manner in which LLU will receive its compensation under this
Agreement with respect to such non-cash consideration will be negotiated in good faith and timely agreed to by the Parties.


 


		3.4	Equity



 


Licensee shall pay fifty thousand
(50,000) of its common shares within thirty (30) days of either the Effective Date or the date this Agreement has been fully executed
by all Parties, whichever is later.


 


		4.	Reports and Plans



 


The reports specified in this
Article 4 will be sent to LLU’s contact identified in Section 18.1. If LLU requests the submission of information
in a particular format, Licensee will use reasonable efforts to comply with such request.


 


		4.1	Quarterly Payment and Milestone Reports



 


On or before each Quarterly Payment
Deadline, Licensee will deliver to LLU a true and accurate report, certified by an officer of Licensee, giving such particulars
of the business conducted by Licensee, its Affiliates and its Sublicensees (including copies of reports provided by Sublicensees
and Affiliates to Licensee) during the preceding Contract Quarter under this Agreement as necessary for LLU to account for Licensee’s
payments, including royalties, hereunder, even if no payments are due. The reports shall continue to be delivered after the termination
or expiration of this Agreement until such time as all Licensed Products permitted to be Sold, if any, have been Sold or destroyed.
The report shall include:


 


		(a)	The name of the
                                         Licensee, the title and date of this Agreement, and the period covered by the report;



 


		(b)	The name of any Affiliates and Sublicensees
                                         whose activities are also covered by the report;



 


		(c)	Identification of each Licensed Product and Licensed Service
                                         for which any royalty payments have become payable;



 


		(d)	Net Product Sales and Net Service
                                         Sales segregated on a product-by-product, service-by service, and a country-by-country
                                         basis, or an affirmative statement that no Sales were made. The report shall also itemize
                                         the permitted deductions from the Gross Consideration used to arrive at the resulting
                                         Net Product Sales and Net Service Sales, on a product-by-product, service-by service,
                                         and country-by-country basis;



 


		(e)	The applicable royalty rate;



 


		(f)	An affirmative statement of whether
                                         any milestones with deadlines in that Contract Quarter under Section 2.4 and any
                                         milestones under Section 3.1(c) were achieved or not achieved, and the resulting
                                         Milestone Fee payable;



 




    8


     


    

 


		(g)	Non-Royalty Sublicensing Consideration
                                         received by Licensee segregated on a Sublicense-by-Sublicense basis, or an affirmative
                                         statement that none was received;



 


		(h)	If any consideration was received in currencies other than U.S.
                                         dollars, the report shall describe the currency exchange calculations; and



 


		(i)	Any changes in accounting methodologies used to account for and
                                         calculate the items included in the report since the previous report.



 


		4.2	Annual
                                         Written Progress Report and Commercialization Plan



 


Within forty-five (45) days following
the end of each Contract Year, Licensee will deliver to LLU a true and accurate signed written progress report that summarizes
(a) Licensee’s efforts and accomplishments during the Contract Year to diligently commercialize Licensed Products and Licensed
Services, and (b) Licensee’s development and commercialization plans with respect to Licensed Products and Licensed Services
for the next Contract Year. The report shall also cover such activities by Affiliates and Sublicensees. The report shall contain
the following information to the extent relevant to the activities under this Agreement:


 


		(i)	The name of the Licensee, the title
                                         and date of this Agreement, the names of any Affiliates and Sublicensees, and the products
                                         and services being developed and/or commercialized;



 


		(ii)	The progress toward completing and the plans for completing
                                         the applicable milestone events pursuant to Sections 2.4 and 3.1(c); and



 


		(iii)	The research and development activities,
                                         including status and plans for obtaining any necessary Regulatory Approvals, performed
                                         during the past year, and the plans for research and development activities for the next
                                         year.



 


		5.	Payment, Records, and Audits



 


		5.1	Payments



 


All amounts
referred to in this Agreement are expressed in U.S. dollars without deductions for taxes, assessments, fees, or charges of any
kind. All payments to LLU will be made in U.S. dollars by check or wire transfer (Licensee to pay all wire transfer fees) as specified
in Section 18.2.


 


		5.2	Sales Outside the U.S.



 


If any currency conversion shall
be required in connection with the calculation of payments hereunder, such conversion shall be made using the rate used by Licensee
for its financial reporting purposes in accordance with Generally Accepted Accounting Principles (or foreign equivalent) or, in
the absence of such rate, using the average of the buying and selling exchange rate for conversion between the foreign currency
and U.S. Dollars, for current transactions as reported in The Wall Street Journal on the last business day of the Contract
Quarter to which such payment pertains.


 


		5.3	Late Payments



 


Amounts that are not paid by Licensee
when due will accrue a late charge from the due date until paid, at a rate equal to one percent (1.0%) per month (or the maximum
allowed by law, if less). If Licensee is more than thirty (30) days in arrears on any payment or obligation due under this Agreement,
LLU and Prosecution Counsel shall have no obligation to confer or otherwise communicate with, or provide any information to, Licensee
under Article 6 of this Agreement, until Licensee becomes current on all payments and obligations under this Agreement.




    9


     


    

 


		5.4	Records



 


For a period of six (6) years
after the Contract Quarter to which the records pertain, Licensee shall keep, and shall cause its Affiliates and each Sublicensees
to keep, complete and accurate records of their Sales, Net Product Sales, Net Service Sales, Milestone Fees, and Non-Royalty Sublicensing
Consideration in sufficient detail to enable such payments to be determined and audited.


 


		5.5	Auditing



 


Licensee and its Affiliates will
permit LLU or its representatives, at LLU’s expense, to periodically examine books, ledgers, and records during regular
business hours, at Licensee’s or its Affiliate’s place of business, on at least thirty (30) days advance notice, to
the extent necessary to verify any payment or report required under this Agreement. For each Sublicensee, Licensee shall obtain
such audit rights for LLU or itself. If Licensee obtains such audit rights for itself, Licensee will promptly conduct an audit
of the Sublicensee’s records upon LLU’s request, and Licensee will furnish to LLU a copy of the findings from such
audit. No more than one audit of Licensee, each Affiliate, and each Sublicensee shall be conducted under this Section 5.5
in any calendar year. If any amounts due LLU have been underpaid, then Licensee shall immediately pay LLU the amount of such underpayment
plus accrued interest due in accordance with Section 5.3. If the amount of underpayment is equal to or greater than five
percent (5%) of the total amount due for the records so examined, Licensee will pay the cost of such audit. Such audits may, at
LLU ’s sole discretion, consist of a self-audit conducted by Licensee at Licensee’s expense and certified in writing
by an authorized officer of Licensee. All information examined pursuant to this Section 5.5 shall be deemed to be the Confidential
Information of the Licensee.


 


		6.	Patent Expenses and Prosecution



 


		6.1	Patent Expenses



 


Licensee shall pay for filing,
prosecuting, defending and maintaining Patent Rights and related patent searches, for so long as and in such countries as this
Agreement remains in effect (“Patent Expenses”).


 


		6.2	Patent Prosecution



 


Licensee shall instruct Prosecution
Counsel directly for the prosecution and maintenance of the Patent Rights, although Licensee must remain in good standing with
this Agreement for this permission to instruct Prosecution Counsel to remain in place. Upon filing, Licensee will provide LLU
with copies of all applications for all such Patent Rights, and all other material submissions and correspondence with any patent
authorities regarding such Patent Rights, in sufficient time for review and comment prior to filing, to the extent practicable
under the circumstances. In addition, Licensee will provide LLU and its counsel with an opportunity to consult with Licensee and
its counsel regarding prosecution and maintenance of any such Patent Rights, and Licensee will not unreasonably refuse to address
all reasonable comments timely made by or on behalf of LLU. In the event of any breach of this Agreement by Licensee, LLU may
elect to take over the prosecution and maintenance of the Patent Rights at any time. The Parties agree that they share a common
legal interest to get valid enforceable patents and that Licensee will maintain as privileged all information received pursuant
to this Section 6.2. Notwithstanding Section 18.1, the Parties may, at their own discretion, provide (or instruct Prosecution
Counsel to provide) documents and communications regarding patent prosecution and maintenance to the other Party or the other
Party’s designee by email or regular U.S. mail.


 




    10


     


    

 


		6.3	Ownership



 


All patent applications and patents
directly related and capable of claiming priority to the Patent Rights will be in the name of LLU and owned by LLU. No payments
due under this Agreement will be reduced as the result of co-ownership interests in the Patent Rights by Licensee or any other
party, wherein ownership or co-ownership is established by inventorship as determined in accordance with United States patent
law.


 


		6.4	Non-Pursued
                                         Patent Rights



 


If Licensee does not choose to
pursue patent rights in a particular jurisdiction and LLU chooses to do so, then in each such case Licensee shall so notify LLU,
promptly in writing and in good time to enable LLU to meet any deadlines by which an action must be taken, but no less than thirty
(30) days of such deadlines, to preserve such patent rights in such jurisdiction, Licensee shall so notify LLU and thereafter
said patent rights on the basis of any particular claim, patent application or patent, as appropriate, shall no longer be included
in the Patent Rights and Licensee shall have no further rights thereto.


 


		6.5	Withdrawal
                                         from Paying Patent Expenses



 


If at any time Licensee wishes
to cease paying Patent Expenses for a particular Patent Right or for patent prosecution or maintenance for a patent or patent
application in a particular jurisdiction, Licensee must give LLU at least sixty (60) days prior written notice and Licensee will
continue to be obligated to pay for the Patent Expenses which reasonably accrue with respect thereto during said notice period.
Thereafter, said particular Patent Right, patent application, or patent shall no longer be included in the Patent Rights and Licensee
shall have no further rights thereto.


 


		6.6	U.S.
                                         Patent and Trademark Office Entity Size Status



 


Licensee represents that as of
the Effective Date the entity size status of Licensee in accordance with the regulations of the U.S. Patent and Trademark Office
is as set forth in Exhibit A. Licensee will inform LLU in writing on a timely basis of any change in its U.S. Patent and
Trademark Office entity size status.


 


		7.	Term and Termination



 


		7.1	Term



 


Unless earlier terminated as provided
herein, the term of this Agreement is from the Effective Date until the last to occur of: (a) the expiration of all patents issued
under Patent Rights (if any) and the cancellation, withdrawal, or express abandonment of all patent applications under Patents
Rights (if any), or (b) the date required for Licensee to pay any Milestone Fees in Section 3.1(c) or running royalties
in Section 3.2(b).


 


		7.2	Termination by Licensee



 


Licensee,
at its option, may terminate this Agreement, provided Licensee is not in default on any of its obligations under this Agreement,
by providing LLU written notice of intent to terminate, which such termination will be effective ninety (90) days following receipt
of such notice by LLU.


 






    11


     


    

 


		7.3	Termination by LLU



 


LLU may immediately
terminate this Agreement, or Licensee’s rights with respect to any part of Licensed Subject Matter, or any part of Field, or any
part of Territory, or the exclusive nature of the license grant, upon delivery of written notice to Licensee of LLU’s decision
to terminate, if any of the following occur:





 


		(a)	Licensee becomes in arrears
                                         in any payments due under this Agreement and Licensee fails to make the required payment
                                         within ninety (90) days after delivery of written notice from LLU (except for the Upfront
                                         License Fee in Section 3.1(b)(i), for which no cure period applies); or



 


		(b)	Licensee is in breach of any
                                         non-payment provision of this Agreement, and does not cure such breach within ninety
                                         (90) days after delivery of written notice from LLU; or



 


		(c)	LLU delivers notice to Licensee
                                         of three or more actual breaches of this Agreement in any twelve- (12-) month period,
                                         even in the event that Licensee cures such breaches in the allowed period, provided that
                                         this Section 7.3(c) does not apply to Sublicensee breaches cured by Licensee under
                                         Section 2.3(c); or



 


		(d)	Licensee or its Affiliate or
                                         Sublicensee initiates any proceeding or action to challenge the validity, enforceability,
                                         or scope of one or more of the Patent Rights, or assists a third party in pursuing such
                                         a proceeding or action.



 


		7.4	Other
                                         Conditions of Termination



 


This Agreement will terminate:


 


		(a)	Immediately without the necessity of any action being
taken by LLU or Licensee: (i) if Licensee becomes bankrupt or insolvent; (ii) Licensee’s board of directors elects
to liquidate its assets or dissolve its business; (iii) Licensee ceases its business operations; (iv) Licensee makes an assignment
for the benefit of creditors; or (v) if the business or assets of Licensee are otherwise placed in the hands of a receiver, assignee
or trustee, whether by voluntary act of Licensee or otherwise; or



 


		(b)	At any time by mutual written agreement between Licensee and
                                         LLU; or



 


		(c)	Immediately, upon written notice from LLU to Licensee, if
                                         the Upfront License Fee specified in Section 3.1(b)(i) is not timely paid.



 


		7.5	Effect
                                         of Termination



 


If this Agreement is terminated for any reason:


 


		(a)	All rights and licenses of Sublicensees
                                         shall terminate upon termination of this Agreement; provided however, if the Sublicense
                                         Agreement is for all of the Field for all of the Territory, and the Sublicensee is in
                                         good standing and agrees in writing to assume all of the obligations of Licensee and
                                         provides LLU with written notice thereof within thirty (30) days after termination of
                                         this Agreement, then such Sublicense Agreement shall survive; and



 


		(b)	Licensee (and any Affiliates
                                         or Sublicensees) shall cease making, having made, distributing, having distributed, using,
                                         selling, offering to sell, leasing, loaning and importing any Licensed Products and performing
                                         Licensed Services by the effective date of termination; and



 


		(c)	Licensee shall tender payment
                                         of all accrued royalties and other payments due to LLU as of the effective date of termination
                                         within thirty (30) days thereafter; and





    12


     


    

 


		(d)	Nothing in this Agreement will be construed to release either
                                         Party from any obligation that matured prior to the effective date of termination; and



 


		(e)	The provisions of Articles
                                         8 (Confidentiality), 9 (Infringement and Litigation), 11 (Representations
                                         and Disclaimers), 12 (Limit of Liability), 13 (Indemnification), 14
                                         (Insurance), 17 (Use of Name), 18 (Notices), and 19 (General
                                         Provisions) shall survive any termination or expiration of this Agreement. In addition,
                                         the provisions of Article 3 (Compensation), Section 4.1 (Quarterly Payment
                                         and Milestone Reports), Article 5 (Payment, Records and Audits), and Section
                                         6.1 (Patent Expenses) shall survive with respect to all activities and payment obligations
                                         accruing prior to the termination or expiration of this Agreement.



 


		8.	Confidentiality



 


		8.1	Definition



 


“Confidential Information”
means all information that is of a confidential and proprietary nature to LLU or Licensee and provided by one party (the “Disclosing
Party”) to the other party (the “Receiving Party”) under this Agreement.


 


		8.2	Protection and Marking



 


All Confidential Information
disclosed by Disclosing Party in tangible form, and marked “confidential” and forwarded to the Receiving Party,
or if disclosed orally, is designated as confidential at the time of disclosure: (i) is to be held in strict confidence by
the Receiving Party, (ii) is to be used by the Receiving Party only as authorized in this Agreement, and (iii) shall not be
disclosed by the Receiving Party, its agents or employees without the prior written consent of the Disclosing Party or as
authorized in this Agreement. Licensee has the right to use and disclose Confidential Information of LLU reasonably in
connection with the exercise of its rights under this Agreement, including without limitation disclosing to Affiliates,
Sublicensees, potential investors, acquirers, and others on a need to know basis, if such Confidential Information is
provided under conditions which reasonably protect the confidentiality thereof. The Receiving Party’s obligation of
confidence hereunder includes, without limitation, using at least the same degree of care with the Disclosing Party’s
Confidential Information as Receiving Party uses to protect its own Confidential Information, but always at least a
reasonable degree of care.


 


		8.3	Confidentiality of Terms of Agreement



 


Neither Party shall disclose to
any third party the terms of this Agreement without the prior written consent of the other Party hereto, except each Party may
disclose the terms of this Agreement: (a) to advisors, actual or potential Sublicensees, acquirers or investors, and others on
a need to know basis, in each case, under appropriate confidentiality obligations substantially similar to those of this Article
8. LLU may disclose the existence of this Agreement and the Field to other potential third party licensees for uses outside
the Field. In addition, LLU may disclose relevant non-financial terms (such as patent prosecution, infringement and litigation
obligations) in confidence to other potential third party licensees. Notwithstanding the foregoing, the existence of this Agreement
shall not be considered Confidential Information.


 


		8.4	Disclosure Required by Court Order or
                                         Law



 


If the Receiving Party is required
to disclose Disclosing Party’s Confidential Information, or any terms of this Agreement, pursuant to the order or requirement
of a court, administrative agency, or other governmental body or applicable law, the Receiving Party may disclose such Confidential
Information or terms to the extent required, provided that the Receiving Party shall use reasonable efforts to provide the Disclosing
Party with reasonable advance notice thereof to enable the Disclosing Party to seek a protective order and otherwise seek to prevent
such disclosure. To the extent that Confidential Information so disclosed does not become part of the public domain by virtue
of such disclosure, it shall remain Confidential Information protected pursuant to Article 8.


 




    13


     


    

 


		8.5	Copies



 


The Receiving Party shall not
copy or record any of the Confidential Information of the Disclosing Party, except as reasonably necessary to exercise its rights
or perform its obligations under this Agreement, and for archival and legal purposes.


 


		8.6	Continuing
                                         Obligations



 


Subject to the exclusions listed
in Section 8.7, the Parties’ confidentiality obligations under this Agreement will survive termination of this Agreement
and will continue for a period of five years thereafter.


 


		8.7	Exclusions



 


Information shall not be considered
Confidential Information of a Disclosing Party under this Agreement to the extent that the Receiving Party can establish by competent
written proof that such information:


 


		(a)	Was in the public domain at the time of disclosure; or



 


		(b)	Later became part of the public
                                         domain through no act or omission of the Receiving Party, its employees, agents, successors
                                         or assigns in breach of this Agreement; or



 


		(c)	Was lawfully disclosed to the Receiving Party by a third
                                         party having the right to disclose such information not under an obligation of confidentiality;
                                         or



 


		(d)	Was already known by the Receiving Party at the time of
                                         disclosure; or



 


		(e)	Was independently developed by the Receiving Party without
                                         use of the Disclosing Party’s Confidential Information.



 


		8.8	Copyright
                                         Notice



 


The placement of a copyright notice
on any Confidential Information will not be construed to mean that such information has been published and will not release the
other Party from its obligation of confidentiality hereunder.


 


		8.9	No
                                         Limitation on LLU’s Publication Rights



 


Nothing in this Article 8
shall be construed to limit LLU’s reserved right to publish the scientific findings from research related to Licensed Subject
Matter, as set forth in Section 2.1(c).


 


		9.	Infringement and Litigation



 


		9.1	Notification



 


If LLU’s office for technology
transfer or Licensee becomes aware of any infringement or potential infringement of Patent Rights in the Field, each Party shall
promptly notify the other of such in writing.


 




    14


     


    

 


		9.2	Licensee’s
                                         Enforcement Rights



 


Licensee shall enforce the Patent
Rights against any infringement by a third party in the Field. Licensee shall provide LLU with written notice of its intent to
file an infringement lawsuit at least twenty (20) days before filing. Licensee shall be responsible for payment of all fees and
expenses associated with such enforcement incurred by Licensee and incurred by LLU in providing cooperation or joining as a party
as provided in Section 9.4. Any monetary recovery for actual damages or punitive or enhanced damages in excess of Licensee’s
documented, third-party expenses in enforcing the Patent Rights and amounts actually reimbursed by Licensee to LLU under this
Section 9.2 shall be shared by Licensee with LLU as follows: twenty-five percent (25%) of such monetary recovery shall
be paid to LLU and seventy-five percent (75%) shall be retained by Licensee.


 


		9.3	LLU’s
                                         Enforcement Rights



 


If Licensee does not file suit
within six months after a written request by LLU to initiate an infringement action against an infringer in the Field, then LLU
shall have the right, in its sole discretion, to bring suit to enforce any Patent Right licensed hereunder against the infringing
activities, with LLU retaining all recoveries from such enforcement. If LLU pursues such infringement action, LLU may, as part
of the resolution thereof, grant non-exclusive license rights to the alleged infringer notwithstanding Licensee’s exclusive
license rights.


 


		9.4	Cooperation
                                         between the Parties



 


In any infringement suit or dispute,
the Parties shall cooperate fully with each other. At the request of the Party bringing suit, the other Party will permit reasonable
access, after reasonable advance notice and subject to any confidentiality obligations (including but not limited to restrictions
on access to patient information), to all relevant personnel, records, papers, information, samples, specimens, etc., during regular
business hours. If it is necessary to name LLU as a party in such action, then Licensee must first obtain LLU’s prior written
permission, which permission shall not be unreasonably withheld, provided that LLU shall have reasonable prior input on choice
of counsel on any matter where such counsel represents LLU, and Licensee and such counsel agree to follow all required procedures
requested by LLU General Counsel.


 


		10.	Export Compliance



 


Licensee understands that the
Arms Export Control Act (AECA), including its implementing International Traffic In Arms Regulations (ITAR), and the Export Administration
Act (EAA), including its Export Administration Regulations (EAR), are some (but not all) of the laws and regulations that comprise
the U.S. export laws and regulations. Licensee further understands that the U.S. export laws and regulations include (but are
not limited to): (a) ITAR and EAR product/service/data-specific requirements; (b) ITAR and EAR ultimate destination-specific requirements;
(c) ITAR and EAR end user-specific requirements; (d) Foreign Corrupt Practices Act; and (e) anti-boycott laws and regulations.
Licensee will comply with all then-current applicable export laws and regulations of the U.S. Government (and other applicable
U.S. laws and regulations) pertaining to the Licensed Products and Licensed Services (including any associated products, items,
articles, computer software, media, services, technical data, and other information). Licensee certifies that it will not, directly
or indirectly, export (including any deemed export), or re-export (including any deemed re-export) the Licensed Products and Licensed
Services (including any associated products, items, articles, computer software, media, services, technical data, and other information)
in violation of applicable U.S. laws and regulations. Licensee will include a provision in its agreements, substantially similar
to this Article 10, with its Sublicensees, third party wholesalers and distributors, and physicians, hospitals or other
healthcare providers who purchase a Licensed Product, requiring that these parties comply with all then-current applicable U.S.
export laws and regulations and other applicable U.S. laws and regulations.




    15


     


    

 


		11.	Representations and Disclaimers



 


		11.1	LLU Representations



 


LLU makes no representations or
warranties, express or implied, as to any matter whatsoever including, without limitation: (a) the condition of the Licensed Subject
Matter, the Licensed Product, the Licensed Services or results derived therefrom; or (b) the ownership, merchantability, or fitness
for a particular purpose of the Licensed Subject Matter, the Licensed Product, the Licensed Services or results derived therefrom;
or (c) the scope of the licensed Patent Rights or Technology Rights or that such Patent Rights or Technology Rights may be exploited
by the Licensee without infringing other patents.


 


LLU warrants that it has not previously
granted any rights that would conflict with the rights granted by this Agreement.


 


Licensee, by execution hereof,
acknowledges, covenants and agrees that it has not been induced in any way by the University or its employees to enter into this
Agreement, and further warrants and represents that: (a) it has conducted sufficient due diligence with respect to all items and
issues pertaining to this Article 11 and all other matters pertaining to this Agreement; and (b) the Licensee has adequate
knowledge and expertise, or has utilized knowledgeable and expert consultants, to adequately conduct the due diligence, and agrees
to accept all risks inherent herein.


 


		11.2	Government
                                         Rights



 


Licensee understands that Licensed
Subject Matter may have been developed under a funding agreement with Government and, if so, that Government may have certain
rights relative thereto. This Agreement is made subject to the Government’s rights under any such agreement and under any
applicable Government law or regulation. To the extent that there is a conflict between any such agreement, such applicable law
or regulation and this Agreement, the terms of such Government agreement, and applicable law or regulation, shall prevail. Licensee
shall assure that, to the extent required by U.S. laws and regulations, Licensed Products used or Sold in the U.S. will be manufactured
substantially in the U.S., unless a written waiver is obtained in advance from the U.S. Government.


 


		11.3	LLU
                                         Entity Disclaimers



 


EXCEPT AS SPECIFICALLY SET FORTH
IN SECTION 11.1, LICENSEE UNDERSTANDS AND AGREES THAT NEITHER LLU MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND,
EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, AS TO THE LICENSED PRODUCTS OR LICENSED SERVICES, OR AS TO THE OPERABILITY
OR FITNESS FOR ANY USE OR PARTICULAR PURPOSE, MERCHANTABILITY, SAFETY, EFFICACY, APPROVABILITY BY REGULATORY AUTHORITIES, TIME
AND COST OF DEVELOPMENT, PATENTABILITY, AND/OR BREADTH OF PATENT RIGHTS. NEITHER LLU MAKES ANY REPRESENTATION AS TO WHETHER ANY
PATENT WITHIN PATENT RIGHTS IS VALID, OR AS TO WHETHER THERE ARE ANY PATENTS NOW HELD, OR WHICH WILL BE HELD, BY OTHERS OR BY
LLU THAT MIGHT BE REQUIRED FOR USE OF PATENT RIGHTS IN FIELD. LLU MAKES NO REPRESENTATION THAT THE INVENTIONS CONTAINED IN PATENT
RIGHTS DO NOT INFRINGE ANY OTHER PATENTS NOW HELD OR THAT WILL BE HELD BY OTHERS OR BY LLU. NOTHING IN THIS AGREEMENT WILL BE
CONSTRUED AS CONFERRING BY IMPLICATION, ESTOPPEL OR OTHERWISE ANY LICENSE OR RIGHTS TO ANY PATENTS OR TECHNOLOGY OF LLU OTHER
THAN THE PATENT RIGHTS, WHETHER SUCH PATENTS ARE DOMINANT OR SUBORDINATE TO THE PATENT RIGHTS, OR THE TECHNOLOGY RIGHTS SPECIFICALLY
DESCRIBED HEREIN.




    16


     


    

 


		11.4	Licensee
                                         Representations



 


By execution of this Agreement,
Licensee represents, warrants, acknowledges, covenants and agrees (a) that Licensee has not been induced in any way by LLU or
its employees to enter into this Agreement, and (b) that Licensee has been given an opportunity to conduct sufficient due diligence
with respect to all items and issues pertaining to this Article 11 (Representations and Disclaimers) and all other matters
pertaining to this Agreement; and (c) that Licensee has adequate knowledge and expertise, or has utilized knowledgeable and expert
consultants, to adequately conduct the due diligence, and (d) that Licensee accepts all risks inherent herein. Licensee represents
that it is a duly organized, validly existing entity of the form indicated in the preamble to this Agreement, and is in good standing
under the laws of its jurisdiction of organization as indicated in the preamble of this Agreement, and has all necessary corporate
or other appropriate power and authority to execute, deliver and perform its obligations hereunder.


 


		12.	Limit of Liability



 


IN NO EVENT SHALL LLU, ITS MEMBER
INSTITUTIONS, OR THEIR RESPECTIVE INVENTORS, MEMBERS OF THE BOARD OF TRUSTEES, OFFICERS, EMPLOYEES, STUDENTS, AGENTS OR AFFILIATED
ENTERPRISES, BE LIABLE FOR ANY INDIRECT, SPECIAL, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY, OR PUNITIVE DAMAGES (INCLUDING, WITHOUT
LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER,
REGARDLESS OF WHETHER THE FOREGOING OR ANY PARTY HERETO KNOWS OR SHOULD KNOW OF THE POSSIBILITY OF SUCH DAMAGES. OTHER THAN FOR
CLAIMS AGAINST LICENSEE FOR INDEMNIFICATION (ARTICLE 13) OR FOR MISUSE OR MISAPPROPRIATION OR INFRINGEMENT OF LLU’S INTELLECTUAL
PROPERTY RIGHTS OR BREACH OF DUTY TO MAINTAIN CONFIDENTIAL INFORMATION, LICENSEE WILL NOT BE LIABLE TO LLU FOR ANY INDIRECT, SPECIAL,
CONSEQUENTIAL OR PUNITIVE DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR REVENUE) ARISING OUT OF OR IN
CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER, REGARDLESS OF WHETHER LICENSEE KNOWS OR SHOULD HAVE KNOWN OF THE POSSIBILITY
OF SUCH DAMAGES.


 


		13.	Indemnification



 


		13.1	Indemnification Obligation



 


SUBJECT TO SECTION 13.2,
LICENSEE SHALL HOLD HARMLESS, DEFEND AND INDEMNIFY LLU, ITS MEMBER INSTITUTIONS, AND THEIR RESPECTIVE MEMBERS OF THE BOARD OF
TRUSTEES, OFFICERS, EMPLOYEES, STUDENTS AND AGENTS (“INDEMNIFIED PARTIES”) FROM AND AGAINST ANY LIABILITIES,
DAMAGES, CAUSES OF ACTION, SUITS, JUDGMENTS, LIENS, PENALTIES, FINES, LOSSES, COSTS AND EXPENSES (INCLUDING, WITHOUT LIMITATION,
REASONABLE ATTORNEYS’ FEES AND OTHER EXPENSES OF LITIGATION) (COLLECTIVELY “LIABILITIES”) RESULTING FROM
CLAIMS OR DEMANDS BROUGHT BY THIRD PARTIES AGAINST AN INDEMNIFIED PARTY ON ACCOUNT OF ANY INJURY OR DEATH OF PERSONS, DAMAGE TO
PROPERTY, OR ANY OTHER DAMAGE OR LOSS ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR THE EXERCISE OR PRACTICE BY OR UNDER
AUTHORITY OF LICENSEE, ITS AFFILIATES OR THEIR SUBLICENSEES, OR THIRD PARTY WHOLESALERS OR DISTRIBUTORS, OR PHYSICIANS, HOSPITALS
OR OTHER HEALTHCARE PROVIDERS WHO PURCHASE A LICENSED PRODUCT OR LICENSED SERVICE, OF THE RIGHTS GRANTED BY LLU UNDER THIS AGREEMENT.


 




    17


     


    

 


		13.2	Conditions
                                         of Indemnification



 


Licensee shall have no responsibility or obligation
under Section 13.1 for any Liabilities to the extent caused by the gross negligence or willful misconduct of LLU.


 


		14.	Insurance



 


		14.1	Insurance Requirements



 


Prior to any Licensed Product
being used or Sold (including for the purpose of obtaining Regulatory Approval), and prior to any Licensed Service being performed
by Licensee, an Affiliate, or by a Sublicensee, and for a period of five years after this Agreement expires or is terminated,
Licensee shall, at its sole cost and expense, procure and maintain commercial general liability insurance in commercially reasonable
and appropriate amounts for the Licensed Product being used or Sold or the Licensed Service being performed. Licensee shall use
commercially reasonable efforts to have the LLU, its member institutions, and their respective Regents, officers, employees, and
Inventors named as additional insureds. Such commercial general liability insurance shall provide, without limitation: (a) product
liability coverage; (b) broad form contractual liability coverage for Licensee’s indemnification under this Agreement; and
(c) coverage for litigation costs.


 


		14.2	Evidence of Insurance and Notice of Changes



 


Upon request by LLU, Licensee
shall provide LLU with written evidence of the insurance referenced in Section 14.1 above. Additionally, Licensee shall
provide LLU with written notice of at least sixty (60) days prior to Licensee cancelling, not renewing, or materially changing
such insurance.


 


		15.	Assignment



 


This Agreement may not be assigned
by Licensee without the prior written consent of LLU, which consent will not be unreasonably withheld, except Licensee may assign
this Agreement, without such consent, to any of its Affiliates and/or to an entity that acquires all or substantially all of its
business or assets to which this Agreement pertains, whether by merger, reorganization, acquisition, sale, or otherwise.. A merger
or other transaction in which the equity holders of Licensee prior to such event hold less than a majority of the equity of the
surviving or acquiring entity shall be considered an assignment of this Agreement. For any permitted assignment to be effective,
Licensee must be in good standing under this Agreement, and the assignee must assume in writing (a copy of which shall be promptly
provided to LLU) all of Licensee’s interests, rights, duties and obligations under this Agreement and agree to comply with
all terms and conditions of this Agreement as if assignee were an original Party to this Agreement.


 


		16.	Marking and Compliance



 


		16.1	Patent Markings



 


Licensee shall assure that all
Licensed Products Sold by Licensee, Affiliates, or Sublicensees will be legibly marked with the number of any applicable patent(s)
licensed hereunder as part of the Patent Rights in accordance with each country’s patent marking laws, including Title
35, U.S. Code, or if such marking is not practicable, that the accompanying outer box or product insert for Licensed Products
is marked accordingly.


 




    18


     


    

 


		16.2	Governmental Approvals and Marketing
                                         of Licensed Products and or Licensed Services



 


Licensee will be responsible for
obtaining all necessary governmental approvals for the development, production, distribution, Sale, and use of any Licensed Product
or performance of any Licensed Service, at Licensee’s expense, including, without limitation, any safety studies. Licensee
will have sole responsibility for any warning labels, packaging and instructions as to the use and the quality control for any
Licensed Product or Licensed Service.


 


		16.3	Foreign
                                         Registration and Laws



 


Licensee shall register this Agreement
with any foreign governmental agency that requires such registration and Licensee will pay all costs and legal fees in connection
with such registration. Licensee is responsible for compliance with all foreign laws affecting this Agreement or the Sale of Licensed
Products and Licensed Services to the extent there is no conflict with United States law, in which case United States law will
control.


 


		17.	Use of Name



 


Licensee will not use the name,
trademarks or other marks of LLU, or any of its respective employees or Regents, without the advance written consent of LLU. LLU
may use Licensee’s name and logo for annual reports, brochures, website and internal reports without prior consent.


 


		18.	Notices and Payments



 


		18.1	Any notice of the Parties required or permitted
                                         to be given or made under this Agreement will be in writing and will be deemed effective
                                         when sent in a manner that provides confirmation or acknowledgement of delivery and received
                                         at the mailing address or Fax number set forth below (unless changed by written notice
                                         pursuant to this Section 18.1).



 


	Licensee
    Contact Information	 	LLU
    Contact Information
	Contact for Notice	 	Contact for Notice
	Attn: Amro Albanna, CEO	 	Attn: Kent Hansen, General Counsel
	11161 Anderson St., Suite 105-10014	 	Loma Linda University Health
	Loma Linda, CA 92354	 	24890 Tulip Avenue
	Tel: (951) 316-9002	 	Loma Linda, California 92354
	Email: aalbanna@aditxt.com	 	Fax: 909-558-2655
	 	 	khansen@llu.edu


 


Each Party shall update the other Party in writing
with any changes in its contact information.


 


		18.2	All amounts payable hereunder
                                         by Licensee will be paid in United States funds without deductions for taxes, assessments,
                                         fees, or charges of any kind. Payments are to be made to Loma Linda University Health
                                         by wire transfer to:



 


[_____________]


 




    19


     


    

 


REFERENCE: include title and Effective Date of Agreement
and type of payment.


 


		19.	General Provisions



 


		19.1	Binding Effect



 


This Agreement is binding upon
and inures to the benefit of the Parties hereto, their respective executors, administrators, heirs, permitted assigns, and permitted
successors in interest.


 


		19.2	Construction of Agreement



 


Headings are included for convenience
only and will not be used to construe this Agreement. The Parties acknowledge and agree that both Parties substantially participated
in negotiating the provisions of this Agreement; therefore, both Parties agree that any ambiguity in this Agreement shall not
be construed more favorably toward one Party than the other Party, regardless of which Party primarily drafted this Agreement.


 


		19.3	Counterparts and Signatures



 


This Agreement may be executed
in multiple counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and
the same instrument.


 


		19.4	Compliance with Laws



 


Licensee will comply with all applicable federal, state
and local laws and regulations, including, without limitation, all export laws and regulations.


 


		19.5	Governing Law



 


This Agreement will be construed
and enforced in accordance with laws of the U.S. and the State of California, without regard to any choice of law and/or conflicts
of law principles that would otherwise refer to and apply the laws of another jurisdiction.


 


		19.6	Modification



 


Any modification of this Agreement
will be effective only if it is in writing and signed by duly authorized representatives of both Parties. No modification will
be made by email communications.


 


		19.7	Severability



 


If any provision hereof is held
to be invalid, illegal or unenforceable in any jurisdiction, the Parties hereto shall negotiate in good faith a valid, legal and
enforceable substitute provision that most nearly reflects the original intent of the Parties, and all other provisions hereof
shall remain in full force and effect in such jurisdiction and shall be construed in order to carry out the intentions of the
Parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality
or enforceability of such other provisions in any other jurisdiction, so long as the essential essence of this Agreement remains
enforceable.


 


		19.8	Third Party Beneficiaries



 


Nothing in this Agreement, express
or implied, is intended to confer any benefits, rights or remedies on any entity, other than the Parties and their permitted successors
and assigns.


 




    20


     


    

 


		19.9	Waiver



 


Neither Party will be deemed to
have waived any of its rights under this Agreement unless the waiver is in writing and signed by such Party. No delay or omission
of a Party in exercising or enforcing a right or remedy under this Agreement shall operate as a waiver thereof.


 


		19.10	Entire
                                         Agreement



 


This Agreement constitutes the
entire agreement between the Parties regarding the subject matter hereof, and supersedes all prior written or verbal agreements,
representations and understandings relative to such matters.


 


		19.11	Grant
                                         of Security Interest



 


Licensee hereby grants to LLU
a security interest in and to Licensee’s rights under this Agreement, as collateral security for the payment by Licensee of any
and all sums that may be owed from time to time by Licensee to LLU. LLU shall have all rights of a secured party as specified
in the California Uniform Commercial Code relative to this security interest and the enforcement thereof. Licensee hereby authorizes
LLU to file with the appropriate governmental agencies appropriate UCC-1 financing statements to evidence this security interest.


 


		20.	No Other Promises and Agreements;
                                         Representation by Counsel.



 


Licensee hereby expressly states,
warrants and represents that no promise or agreement which is not herein expressed has been made to Licensee in executing this
Agreement except those explicitly set forth herein, and that Licensee is not relying upon any statement or representation of LLU
or its representatives. Licensee is relying on Licensee’s own judgment and has had the opportunity to be represented by
legal counsel. Licensee hereby warrants and represents that Licensee understands and agrees to all terms and conditions set forth
in this Agreement.


 


IN WITNESS WHEREOF, the Parties hereto have
caused their duly authorized representatives to execute this Agreement.


 


	LOMA LINDA UNIVERSITY HEALTH	 	ADITX THERAPEUTICS INC
	 	 	 
	By	/s/ Rodney
    Neal	 	By	/s/ Amro
    Albanna
	 	 	 
	Printed Name: Rodney Neal	 	Printed Name: Amro Albanna
	 	 	 
	Title: Sr. Vice Pres., Finance	 	Title: CEO
	 	 	 
	Date: 3/15/2018	 	Date: 3/15/2018


 







    21


     


    

 


EXHIBIT A


 


PATENT RIGHTS


 


 


 


 


 


22